| Bioactivity | Mal-VC-PAB-DMEA-PNU-159682 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-topoisomerase II agent, PNU-159682, linked via the lysosomally cleavable dipeptide, Mc-VC-PAB. Mal-VC-PAB-DMEA-PNU-159682 can be used in the synthesis of Anti-CD22-NMS249 (HY-164761)[1]. |
| CAS | 1178887-17-6 |
| Formula | C66H83N9O22 |
| Molar Mass | 1354.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shang-Fan Yu, et al. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Clin Cancer Res. 2015 Jul 15;21(14):3298-306. |
Mal-VC-PAB-DMEA-PNU-159682
CAS: 1178887-17-6 F: C66H83N9O22 W: 1354.41
Mal-VC-PAB-DMEA-PNU-159682 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-topoisom
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.